Retinal Vein Occlusion
Ophthalmology·MeSH: Retinal Vein Occlusion
Prevalence
30.0 / 100K
5 drugs in development·5 companies·1 clinical trial
Drug Pipeline by Phase
Approved(2)
Phase 3(1)
| Drug | Company |
|---|---|
| m710 | MOMENTA PHARMACEUTICALS INC (MNTA) |
Phase 2(1)
| Drug | Company |
|---|---|
| ar-1105 | AERIE PHARMACEUTICALS INC (AERI) |
Preclinical(1)
Compare drugs
Frequently asked questions
How many drugs are in development for Retinal Vein Occlusion?
BioSniper tracks 5 drugs in development for Retinal Vein Occlusion across 5 companies.
How many clinical trials target Retinal Vein Occlusion?
There are 1 clinical trial targeting Retinal Vein Occlusion tracked by BioSniper.
What is the prevalence of Retinal Vein Occlusion?
The estimated prevalence of Retinal Vein Occlusion is approximately 30.0 per 100,000 population.
Deep-dive into Retinal Vein Occlusion
Full trial data, competitive analysis, and AI-powered pipeline tracking.
Start Free Analysis